Trial · NCT01993667
Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
NCT01993667, Phase 4, Completed, University of Utah; results first posted 2019-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing. Trials, record NCT01993667. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01993667
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
- NCT number
- NCT01993667
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 130 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- Prophylaxis of Acute Mountain Sickness
- Interventions
- Low Dose Acetazolamide, Normal Dose Acetazolamide
- First posted
- 2013-11-25
- Last updated
- 2019-01-29
- Results first posted
- 2019-01-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score | 12 days | Lake Louise Score, A total score of 3 to 5 indicates mild AMS. A score of 6 or more signifies severe AMS. Minimum value - 0, Maximum = 15 |
| Secondary | Number of Participants With Side Effects | 12 days | The typical side effects of acetazolamide will be measured daily (paresthesias of fingers and toes, change in urination frequency, and change in taste of beverages). The side effect questionnaire included the following questions: In the past 12 h, have you experienced the following symptoms: Tingling of toes? Tingling of fingers? Increase in urination? Taste change of beverages? Symptoms were self-reported and rated on a 0-5 scale (0=none, 5=maximum) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score | 12 days | Seventy-three participants had sufficient data to be included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Side Effects | 12 days | These participants had sufficient data to be included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score | Acetazolamide Normal Dose | 21 | Participants | ||
| Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score | Acetazolamide Low Dose | 21 | Participants | ||
| Number of Participants With Side Effects | Acetazolamide Normal Dose | 6 | Participants | ||
| Number of Participants With Side Effects | Acetazolamide Low Dose | 7 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Acetazolamide Normal Dose | 64 | |
| Overall Study | STARTED | Acetazolamide Low Dose | 66 | |
| Overall Study | COMPLETED | Acetazolamide Normal Dose | 43 | |
| Overall Study | COMPLETED | Acetazolamide Low Dose | 47 | |
| Overall Study | NOT COMPLETED | Acetazolamide Normal Dose | 21 | |
| Overall Study | NOT COMPLETED | Acetazolamide Low Dose | 19 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acetazolamide Normal Dose | 0 | 43 |
| Total, all-cause mortality | Acetazolamide Low Dose | 0 | 47 |
| Total, other adverse events | Acetazolamide Normal Dose | 0 | 43 |
| Total, other adverse events | Acetazolamide Low Dose | 0 | 47 |
| Total, serious adverse events | Acetazolamide Normal Dose | 0 | 43 |
| Total, serious adverse events | Acetazolamide Low Dose | 0 | 47 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Acetazolamide Normal Dose vs Acetazolamide Low Dose: Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score | Trial comparisons |
| Acetazolamide Normal Dose vs Acetazolamide Low Dose: Number of Participants With Side Effects | Trial comparisons |
| Acetazolamide Normal Dose vs Acetazolamide Low Dose: deaths from any cause | Trial comparisons |
| Acetazolamide Normal Dose vs Acetazolamide Low Dose: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01993667
GET https://conductscience.org/api/trials/v1/NCT01993667/registered